TitleInhibition of SARS-CoV-2 in Vero cell cultures by peptide-conjugated morpholino oligomers.
Publication TypeJournal Article
Year of Publication2021
AuthorsRosenke, K, Leventhal, S, Moulton, HM, Hatlevig, S, Hawman, D, Feldmann, H, Stein, DA
JournalJ Antimicrob Chemother
Volume76
Issue2
Pagination413-417
Date Published2021 01 19
ISSN1460-2091
KeywordsAnimals, Antiviral Agents, Cell Survival, Cell-Penetrating Peptides, Chlorocebus aethiops, COVID-19, Cytopathogenic Effect, Viral, Morpholinos, SARS-CoV-2, Vero Cells, Virus Replication
Abstract

BACKGROUND: As the causative agent of COVID-19, SARS-CoV-2 is a pathogen of immense importance to global public health. Development of innovative direct-acting antiviral agents is sorely needed to address this virus. Peptide-conjugated morpholino oligomers (PPMO) are antisense compounds composed of a phosphorodiamidate morpholino oligomer covalently conjugated to a cell-penetrating peptide. PPMO require no delivery assistance to enter cells and are able to reduce expression of targeted RNA through sequence-specific steric blocking.

METHODS: Five PPMO designed against sequences of genomic RNA in the SARS-CoV-2 5'-untranslated region and a negative control PPMO of random sequence were synthesized. Each PPMO was evaluated for its effect on the viability of uninfected cells and its inhibitory effect on the replication of SARS-CoV-2 in Vero-E6 cell cultures. Cell viability was evaluated with an ATP-based method using a 48 h PPMO treatment time. Viral growth was measured with quantitative RT-PCR and TCID50 infectivity assays from experiments where cells received a 5 h PPMO treatment time.

RESULTS: PPMO designed to base-pair with sequence in the 5' terminal region or the leader transcription regulatory sequence region of SARS-CoV-2 genomic RNA were highly efficacious, reducing viral titres by up to 4-6 log10 in cell cultures at 48-72 h post-infection, in a non-toxic and dose-responsive manner.

CONCLUSIONS: The data indicate that PPMO have the ability to potently and specifically suppress SARS-CoV-2 growth and are promising candidates for further preclinical development.

DOI10.1093/jac/dkaa460
Alternate JournalJ Antimicrob Chemother
PubMed ID33164048
PubMed Central IDPMC7717290